Minneapolis, Minn. – Nov. 26, 2018 – Minneapolis Heart Institute Foundation® (MHIF) announced the first successful implantation using the LivaNova-Caisson transcatheter Mitral valve replacement (TMVR) system, performed by physicians at the Minneapolis Heart Institute® at Abbott Northwestern Hospital. MHIF physicians are conducting a research study using the novel technology for patients with severe mitral regurgitation.
Mitral regurgitation (MR) is a debilitating, progressive and life-threatening disease in which a leaky mitral valve causes a backward flow of blood in the heart. In the U.S., MR affects nearly one in 10 people age 75 and older. Left untreated, the condition can raise the risk of irregular heartbeats, stroke, and heart failure, which can be deadly. Medications for the condition are limited to symptom management and do not stop the progression of the disease. Open heart mitral valve surgery is the standard treatment, but this invasive procedure is not an option for many patients.
The PRELUDE early feasibility study is designed for patients with symptomatic, severe mitral regurgitation, who are at high risk for cardiovascular surgery. The study is examining the effectiveness of the Caisson TMVR system, a new, substantially less invasive approach to replacing the mitral valve in patients deemed high risk for open-heart surgery.
“We are honored to be part of the PRELUDE study and excited to be able to offer this new, minimally invasive, mitral valve replacement technology to our patients. There is no higher reward for a physician than being able to offer hope to a patient with no other conventional options,” said Mario Goessl, MD, MHIF researcher and investigator who performed the first procedure in the study.
Unlike traditional open-heart surgery, TMVR uses a tube (catheter) through an incision in the groin instead of opening the chest to replace the mitral valve. First, a metal structure called an Anchor, is inserted into the catheter, advanced into the heart and positioned into the opening of the damaged mitral valve. Once the Anchor is in place, the replacement valve is positioned into the Anchor, locking it in place, and the catheter is removed.
“A significant advantage for this system is the transfemoral, transseptal approach, which may facilitate earlier hospital discharge. This possibility is especially important in high-risk patients,” said Paul Sorajja, MD, MHIF researcher and principal investigator in the study.
About the Minneapolis Heart Institute Foundation
The Minneapolis Heart Institute Foundation (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, it is dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.
- Scientific Innovation and Research — MHIF is a recognized research leader in the broadest range of cardiovascular medicine and population health initiatives. Each year MHIF leads more than 175 active research projects and publishes more than 120 peer-reviewed studies. Cardiologists, hospitals and communities around the world adopt MHIF protocols to save lives, improve care and create healthier living opportunities.
- Education and Outreach — MHIF provides more than 10,000 hours of education each year putting its research into practice to improve outcomes. And, MHIF leads cutting-edge, transformative population health research to connect, engage, inform and empower individuals and communities to improve their health.
The Minneapolis Heart Institute Foundation’s work is funded by generous donors and sponsors and supports research initiatives of Minneapolis Heart Institute® at Abbott Northwestern Hospital. Minneapolis Heart Institute® physicians provide care for patients at Abbott Northwestern Hospital in Minneapolis and at 38 community sites across Minnesota and western Wisconsin.